Haematology 2018

A Phase II Study of Pembrolizumab and Involved Site Radiation Therapy (ISRT) for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma PI: Craig Moskowitz, MD , Co-PI: Joachim Yahalom, MD, Santosh Vardhana MD, PhD , Gunjan Shah MD, MS

Study hypothesis

• HDT/ASCT may be overtreating a subset of patients who have excellent outcomes in relapsed HL • Radiation therapy alone can induce durable remissions, particularly in patients with early stage disease at relapse • Radiation therapy induces a diverse repertoire of anti-tumor T cells, but progression is associated with upregulation of the immune checkpoint PD-L1 • Combination of ISRT with anti-PD1 will lead to durable remissions